Jeffrey Eisele Biography and Net Worth

Jeff joined Apellis in September 2020 and is responsible for overseeing clinical development and regulatory affairs, as well as the late-stage development and commercialization of our geographic atrophy program. Jeff brings over 25 years of global experience working at Novartis and Alcon Pharmaceuticals as well as deep expertise in ophthalmology. Prior to Apellis, Jeff was vice President, global biostatistics head, neuroscience and ophthalmology development units at Novartis. He has successfully contributed to the design, execution, and approval of several products across a broad spectrum of disease areas, and his experience spans across biostatistics, clinical development, information technology, clinical operations, and biometrics. Jeff holds a BS in applied mathematics and statistics from The George Washington University, and a MA and PhD in statistics from the University of Michigan. He also completed postdoctoral research funded by the National Eye Institute at the University of Wisconsin-Madison, Department of Biostatistics.

What is Jeffrey Eisele's net worth?: The estimated net worth of Jeffrey Eisele is at least $1.33 million as of January 13th, 2025. Dr. Eisele owns 56,881 shares of Apellis Pharmaceuticals stock worth more than $1,334,030 as of March 31st. This net worth evaluation does not reflect any other investments that Dr. Eisele may own. Learn More about Jeffrey Eisele's net worth.
How do I contact Jeffrey Eisele?: The corporate mailing address for Dr. Eisele and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at investors@apellis.com. Learn More on Jeffrey Eisele's contact information.
Has Jeffrey Eisele been buying or selling shares of Apellis Pharmaceuticals?: Over the course of the past ninety days, Jeffrey Eisele has sold $7,576.80 of Apellis Pharmaceuticals stock. Most recently, Jeffrey Eisele sold 264 shares of the business's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $28.70, for a transaction totalling $7,576.80. Following the completion of the sale, the insider now directly owns 56,881 shares of the company's stock, valued at $1,632,484.70. Learn More on Jeffrey Eisele's trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 29 times. They sold a total of 292,131 shares worth more than $12,067,071.01. The most recent insider tranaction occured on March, 17th when CAO James George Chopas sold 183 shares worth more than $4,542.06. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 3/17/2025.

Jeffrey Eisele Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/13/2025	Sell	264	$28.70	$7,576.80	56,881
12/23/2024	Sell	63	$33.09	$2,084.67	57,145
1/16/2024	Sell	438	$66.81	$29,262.78	72,650
12/26/2023	Sell	68	$57.86	$3,934.48	53,815
2/23/2023	Sell	1,646	$68.76	$113,178.96	53,883
1/30/2023	Sell	883	$52.76	$46,587.08	46,468

Jeffrey Eisele Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $23.45

$23.90

50 Day Range

MA: $27.04

$23.76

$30.76

2 Week Range

Now: $23.45

$23.25

$59.91

Volume

4,306 shs

Average Volume

2,042,004 shs

Market Capitalization

$2.94 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92